Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs

Marta Boffito, Edward Acosta, David Burger, Courtney V. Fletcher, Charles Flexner, Rodolphe Garaffo, Giorgio Gatti, Michael Kurowski, Carlo Federico Perno, Gilles Peytavin, Mario Regazzi, David Back

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) provide a framework for the implementation of TDM in certain defined scenarios in clinical practice. However, the utility of TDM is considered to be on an individual basis until more data are obtained from large clinical trials showing the benefit of TDM. In April 2004, a panel of experts met for the second time in Rome, Italy. This was following the inaugural meeting in Perugia, Italy, in October 2000, which resulted in the manuscript published in AIDS 2002, 16(Suppl 1):S5-S37. The objectives of this second meeting were to review and update the numerous questions surrounding TDM of antiretroviral drugs and discuss the clinical utility, current concerns and future prospects of drug concentration monitoring in the care of HIV-1-infected individuals. A major focus of the meeting was to discuss and critically analyse recent and precedent clinical drug-drug interaction data to provide a clear framework of the pharmacological basis of how one drug may impact the disposition of another. This report, which has been updated to include material published or presented at international conferences up to the end of December 2004, reviews recent pivotal pharmacokinetic interaction data and provides advice to clinical care providers on how some drug-drug interactions may be prevented, avoided or managed, and, when data are available, on what dose adjustments and interventions should be performed.

Original languageEnglish
Pages (from-to)469-477
Number of pages9
JournalAntiviral Therapy
Volume10
Issue number4
Publication statusPublished - 2005

Fingerprint

Drug Monitoring
Drug Interactions
Pharmaceutical Preparations
Italy
Reverse Transcriptase Inhibitors
Manuscripts
Protease Inhibitors
HIV Infections
HIV-1
Acquired Immunodeficiency Syndrome
Pharmacokinetics
Clinical Trials
Pharmacology
Guidelines

ASJC Scopus subject areas

  • Pharmacology

Cite this

Boffito, M., Acosta, E., Burger, D., Fletcher, C. V., Flexner, C., Garaffo, R., ... Back, D. (2005). Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antiviral Therapy, 10(4), 469-477.

Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. / Boffito, Marta; Acosta, Edward; Burger, David; Fletcher, Courtney V.; Flexner, Charles; Garaffo, Rodolphe; Gatti, Giorgio; Kurowski, Michael; Perno, Carlo Federico; Peytavin, Gilles; Regazzi, Mario; Back, David.

In: Antiviral Therapy, Vol. 10, No. 4, 2005, p. 469-477.

Research output: Contribution to journalArticle

Boffito, M, Acosta, E, Burger, D, Fletcher, CV, Flexner, C, Garaffo, R, Gatti, G, Kurowski, M, Perno, CF, Peytavin, G, Regazzi, M & Back, D 2005, 'Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs', Antiviral Therapy, vol. 10, no. 4, pp. 469-477.
Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antiviral Therapy. 2005;10(4):469-477.
Boffito, Marta ; Acosta, Edward ; Burger, David ; Fletcher, Courtney V. ; Flexner, Charles ; Garaffo, Rodolphe ; Gatti, Giorgio ; Kurowski, Michael ; Perno, Carlo Federico ; Peytavin, Gilles ; Regazzi, Mario ; Back, David. / Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. In: Antiviral Therapy. 2005 ; Vol. 10, No. 4. pp. 469-477.
@article{1de9a58ab4664dac820a3fd6d7ac208a,
title = "Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs",
abstract = "The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) provide a framework for the implementation of TDM in certain defined scenarios in clinical practice. However, the utility of TDM is considered to be on an individual basis until more data are obtained from large clinical trials showing the benefit of TDM. In April 2004, a panel of experts met for the second time in Rome, Italy. This was following the inaugural meeting in Perugia, Italy, in October 2000, which resulted in the manuscript published in AIDS 2002, 16(Suppl 1):S5-S37. The objectives of this second meeting were to review and update the numerous questions surrounding TDM of antiretroviral drugs and discuss the clinical utility, current concerns and future prospects of drug concentration monitoring in the care of HIV-1-infected individuals. A major focus of the meeting was to discuss and critically analyse recent and precedent clinical drug-drug interaction data to provide a clear framework of the pharmacological basis of how one drug may impact the disposition of another. This report, which has been updated to include material published or presented at international conferences up to the end of December 2004, reviews recent pivotal pharmacokinetic interaction data and provides advice to clinical care providers on how some drug-drug interactions may be prevented, avoided or managed, and, when data are available, on what dose adjustments and interventions should be performed.",
author = "Marta Boffito and Edward Acosta and David Burger and Fletcher, {Courtney V.} and Charles Flexner and Rodolphe Garaffo and Giorgio Gatti and Michael Kurowski and Perno, {Carlo Federico} and Gilles Peytavin and Mario Regazzi and David Back",
year = "2005",
language = "English",
volume = "10",
pages = "469--477",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "4",

}

TY - JOUR

T1 - Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs

AU - Boffito, Marta

AU - Acosta, Edward

AU - Burger, David

AU - Fletcher, Courtney V.

AU - Flexner, Charles

AU - Garaffo, Rodolphe

AU - Gatti, Giorgio

AU - Kurowski, Michael

AU - Perno, Carlo Federico

AU - Peytavin, Gilles

AU - Regazzi, Mario

AU - Back, David

PY - 2005

Y1 - 2005

N2 - The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) provide a framework for the implementation of TDM in certain defined scenarios in clinical practice. However, the utility of TDM is considered to be on an individual basis until more data are obtained from large clinical trials showing the benefit of TDM. In April 2004, a panel of experts met for the second time in Rome, Italy. This was following the inaugural meeting in Perugia, Italy, in October 2000, which resulted in the manuscript published in AIDS 2002, 16(Suppl 1):S5-S37. The objectives of this second meeting were to review and update the numerous questions surrounding TDM of antiretroviral drugs and discuss the clinical utility, current concerns and future prospects of drug concentration monitoring in the care of HIV-1-infected individuals. A major focus of the meeting was to discuss and critically analyse recent and precedent clinical drug-drug interaction data to provide a clear framework of the pharmacological basis of how one drug may impact the disposition of another. This report, which has been updated to include material published or presented at international conferences up to the end of December 2004, reviews recent pivotal pharmacokinetic interaction data and provides advice to clinical care providers on how some drug-drug interactions may be prevented, avoided or managed, and, when data are available, on what dose adjustments and interventions should be performed.

AB - The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) provide a framework for the implementation of TDM in certain defined scenarios in clinical practice. However, the utility of TDM is considered to be on an individual basis until more data are obtained from large clinical trials showing the benefit of TDM. In April 2004, a panel of experts met for the second time in Rome, Italy. This was following the inaugural meeting in Perugia, Italy, in October 2000, which resulted in the manuscript published in AIDS 2002, 16(Suppl 1):S5-S37. The objectives of this second meeting were to review and update the numerous questions surrounding TDM of antiretroviral drugs and discuss the clinical utility, current concerns and future prospects of drug concentration monitoring in the care of HIV-1-infected individuals. A major focus of the meeting was to discuss and critically analyse recent and precedent clinical drug-drug interaction data to provide a clear framework of the pharmacological basis of how one drug may impact the disposition of another. This report, which has been updated to include material published or presented at international conferences up to the end of December 2004, reviews recent pivotal pharmacokinetic interaction data and provides advice to clinical care providers on how some drug-drug interactions may be prevented, avoided or managed, and, when data are available, on what dose adjustments and interventions should be performed.

UR - http://www.scopus.com/inward/record.url?scp=23044448423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044448423&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 469

EP - 477

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 4

ER -